Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Brief Summary: The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.

The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.


Options:
A: Arm Label: Dapagliflozin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Placebo for saxagliptin, Drug: Placebo for glimepiride | Arm Label: Dapagliflozin+saxagliptin+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin, Drug: Saxagliptin, Drug: Placebo for glimepiride | Arm Label: Glimepiride+metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Placebo for dapagliflozin, Drug: Placebo for saxagliptin | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Dapagliflozin+saxagliptin+metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for dapagliflozin; Assigned to Arm(s): Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for saxagliptin; Assigned to Arm(s): Dapagliflozin+metformin, Glimepiride+metformin | Intervention Type: DRUG; Name: Placebo for glimepiride; Assigned to Arm(s): Dapagliflozin+metformin, Dapagliflozin+saxagliptin+metformin
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin, Drug: Sulphonylruea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin, Drug: Sulphonylruea | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo | Intervention Type: DRUG; Name: Sulphonylruea; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
C: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg

Answer: D